Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05314621 · ClinicalTrials.gov registry record · Phase 4
A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis
A Phase 4 study, sponsored by Andover Research Eye Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 61
- Enrollment target
NCT05314621: Completed Phase 4 study, sponsored by Andover Research Eye Institute.
NCT05314621 is a Phase 4 study that has completed, run by Andover Research Eye Institute. The registered enrollment target is 61 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05314621, a Phase 4 study, has completed, sponsored by Andover Research Eye Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 61 participants
- Enrollment target
Study Summary
This is a single-center, randomized, double-masked, parallel study.
Primary Outcome
Ocular itching evaluated by the subject at 3(±1) minutes post-CAC (0-4 on the Ocular Itching scale with 4 being the worst, allowing half unit increments) at Visit 3.
Interventions
- DRUG Saline nasal spray
- DRUG Tears Naturale
- DRUG Fluticasone Propionate
- DRUG olopatadine hydrochloride ophthalmic solution 0.7%)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2021-12-31 |
| Est. Completion | 2022-07-24 |
| Phase | Phase 4 |
What the finished NCT05314621 record still lists
NCT05314621 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 4 interventions - of which Saline nasal spray is the first listed.
NCT05314621 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05314621 about?
NCT05314621 is a clinical study titled "A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis". This is a single-center, randomized, double-masked, parallel study.
What is the current status of trial NCT05314621?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 61 participants. The study started on 2021-12-31. Estimated completion is 2022-07-24.
What interventions are being tested in trial NCT05314621?
The interventions under investigation include: Saline nasal spray (DRUG), Tears Naturale (DRUG), Fluticasone Propionate (DRUG), olopatadine hydrochloride ophthalmic solution 0.7%) (DRUG).
Who is sponsoring clinical trial NCT05314621?
This trial is sponsored by Andover Research Eye Institute, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05314621's enrollment target sits among peer trials
61 1119th of 2000 higher than 876 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI